Moderna Reports Second Quarter 2023 Financial Results and Provides Business Updates

Moderna has filed for marketing authorization in the U.S., EU, Canada and Australia for mRNA-1010

Up to $54.3 million CEPI investment aims to help advance Moderna's H5 pandemic influenza vaccine candidate to licensure

Partnership strengthens global preparedness against a significant pandemic threat

If licensed and in the event of an influenza pandemic, Moderna will allocate 20% of its H5 pandemic vaccine manufacturing capacity for timely supply to low- and middle-income countries at affordable pricing